LDE225 + TMZ
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medulloblastoma
Conditions
Medulloblastoma
Trial Timeline
May 6, 2013 → Oct 5, 2016
NCT ID
NCT01708174About LDE225 + TMZ
LDE225 + TMZ is a phase 2 stage product being developed by Novartis for Medulloblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01708174. Target conditions include Medulloblastoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01708174 | Phase 2 | Completed |
Competing Products
9 competing products in Medulloblastoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2940680 + LY2940680 | Eli Lilly | Phase 1 | 33 |
| LDE225 | Novartis | Phase 1/2 | 41 |
| Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine | Brain Biotech | Phase 1 | 25 |
| Modified Measles Virus + Modified Measles Virus Lumbar Puncture | Brain Biotech | Phase 1 | 25 |
| CX 4945 | Brain Biotech | Phase 1/2 | 33 |
| SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years | Brain Biotech | Phase 1 | 25 |
| PEP-CMV | Brain Biotech | Phase 1 | 25 |
| Apatinib Combined With Temozolomide and Etoposide Capsules | Brain Biotech | Phase 2 | 44 |
| Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics | Brain Biotech | Phase 2 | 44 |